Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | LCAT | P04180 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 11/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1025208 | 0.84 | CHRM4 (0.51) | CHRM4LCATPANK3 | |
| SCHEMBL4365334 | 0.84 | CHRM4 (0.48) | CHRM4HRH3LCATFFAR4 | |
| Trifluoroacetic Acid SCHEMBL1025514 | 0.84 | FFAR4 (0.56) | CHRM4HRH3MALT1LCATFFAR4 | |
| SCHEMBL13622626 | 0.81 | CHRM4 (0.56) | CHRM4HRH3MALT1LCATFFAR4 | |
| SCHEMBL4364982 | 0.81 | CHRM4 (0.46) | CHRM4LCATFFAR4 | |
| SCHEMBL1024330 | 0.81 | ALDH1A1 (0.52) | HRH3USP30 | |
| SCHEMBL1025515 | 0.80 | HRH3 (0.55) | CHRM4HRH3MALT1LCATHCRTR1 | |
| SCHEMBL1023389 | 0.78 | KDM4E (0.50) | — | |
| Acetic Acid SCHEMBL1025513 | 0.78 | HRH3 (0.61) | CHRM4HRH3MALT1LCATHCRTR1 | |
| SCHEMBL4364569 | 0.78 | LSS (0.43) | HRH3FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | CHRM4 4834/4885HRH3 1871/4885MALT1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.